Top PDF A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
... roles in the formation and maintenance of tight junctions ...of cancer cells and thus promotes ...carcinogenesis in BC and especially CLDN1 ...between CLDN1 down-regulation and BC ...
10
Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype.
... with poor outcome of breast cancer patients ...enriched in basal-like breast cancers ...validation in an independent series of cases, categorize the accumulation of DKK1 and ...
7
J. Bras. Patol. Med. Lab. vol.51 número6
... Introduction: Breast cancer is the most common visceral malignancy in women, the leading cause of cancer death among women ...The triple negative subgroup has poor ...
10
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
... outcome in the first ...with prognosis we then constructed a simple binary classifier from expression of B-cell- and ...IL-8-metagenes. In contrast, the supervised signature presented here seem to ...
11
LSD1 overexpression is associated with poor prognosis in basal-like breast cancer, and sensitivity to PARP inhibition.
... overexpressed in several types of cancers and linked to poor outcomes. In breast cancer, the significance of LSD1 overexpression is not ...an in silico analysis to assess the ...
12
Protein Expression and Codon 72 Polymorphism of TP53 Gene in Triple Negative Breast Cancer
... 2010). Triple-negative breast cancer (TNBC) is a subtype characterized by the lack of ER, PR, and HER2 expression and is associated with younger age at diagnosis (Dent et ...frequency ...
5
There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population.
... Triple-negative breast cancer (TNBC) is defined by the lack of the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 ...behavior, ...
8
A prognostic model for triple-negative breast cancer patients based on node status, cathepsin-D and Ki-67 index.
... outcome[21–23]. In neoadjuvant chemotherapy (NAC), higher Ki-67 expression is associated with better pathologic complete response (pCR); however, it is a strong prognostic factor for worse survival of patients who ...
7
Increased macroH2A1.1 expression correlates with poor survival of triple-negative breast cancer patients.
... a poor outcome, which is essentially not predicted by assessment of standard clinico- pathological variables, such as lymph node status or tumour size at initial ...targets in the majority of TNBCs implies ...
12
Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas.
... occur in various types of cancer, such as gastric carcinoma [5], prostate cancer [6], oral squamous cell carcinoma [7], and diffuse large B- cell lymphoma ...[8]. In breast ...
9
P02-01. Elicitation of a humoral immune response towards non-immunogenic peptides using the transcriptional transactivator of HIV-1
... articles in all aspects of computational methods used in the analysis and annotation of sequences and structures, as well as all other areas of computational ...
1
Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer
... 21. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor ...
7
Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis
... OS in the high RANK group ...observed in the low RANK group (P=0.634, Figure 2D). In univariate analysis using COX proportional-hazard models, male, advanced pTNM stage, advanced T stage, presence ...
9
Clinics vol.65 número10
... roles in both normal physiological conditions and cancerous condi- tions, EGFR can affect many important characteristics of a cancer’s phenotype, including evasion of apoptosis, prolif- eration, invasion, ...
4
REG4 independently predicts better prognosis in non-mucinous colorectal cancer.
... colorectal cancer, or until end of ...analyzed in two periods (0 to 1.25 and 1.25 to 5 years) in order to meet the assumptions of the Cox model, with the time-dependent Cox ...
8
Inhibition of SK4 Potassium Channels Suppresses Cell Proliferation, Migration and the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer Cells.
... functionally in breast cancer cell lines Four well-characterized breast cancer cell lines, MCF-7, T47D, MDA-MB-231 (MDA-231) and MDA-MB-468 (MDA-468), were ...expressed in MCF-7, ...
17
HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in mice.
... derived breast cancer in mouse and in vitro cell ...implanted in animals’ right flank and randomly assigned to early (1 and 2), starting treatments on day 0, or delayed groups (3 and 4) ...
20
Negative Pressure Wound Therapy in Infected Wound following Posterior Spinal Instrumentation using Simple Self-assembled System: A Case Report
... infection in an instrumented spine patient is often ...instability. Negative pressure wound therapy (NPWT) applied to the spine surgical wound is one of the wound care technique with successful ...implant. ...
3
Rev. Bras. Hematol. Hemoter. vol.38 número2
... The chemotherapy regimen was then changed to a combination of dexamethasone, thalidomide, doxorubicin, cisplatin, cyclophosphamide, and etoposide (DT-PACE). After three cycles of this chemotherapeutic regimen, the mono- ...
4
PTIP associated protein 1, PA1, is an independent prognostic factor for lymphnode negative breast cancer.
... was aromatase inhibitors). For adjuvant therapy, a total of 180 (5β.γ%) of γ44 patients were treated with hormonal therapy, γ6 (10.4%) with chemotherapy which was FEC with or without (w/o) DOC or AC w/o PTX, 81 (βγ.5%) ...
11